We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioequivalence of Two Lispro Formulations

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01133392
First Posted: May 28, 2010
Last Update Posted: December 30, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Eli Lilly and Company
Results First Submitted: October 10, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Healthy Volunteers
Interventions: Drug: Insulin lispro A
Drug: Insulin lispro B

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
41 participants were enrolled into the study. 3 participants discontinued due to subject decision prior to receiving treatment.

Reporting Groups
  Description
Insulin Lispro Dosing Sequence ABAB Each participant was administered insulin lispro A formulation (Treatment A, test – 2 occasions) and insulin lispro B formulation (Treatment B, reference – 2 occasions) in the dosing sequence ABAB. There was an interval of approximately 4 to 7 days between doses.
Insulin Lispro Dosing Sequence BABA Each participant was administered insulin lispro A formulation (Treatment A, test – 2 occasions) and insulin lispro B formulation (Treatment B, reference – 2 occasions) in the dosing sequence BABA. There was an interval of approximately 4 to 7 days between doses.

Participant Flow for 7 periods

Period 1:   First Intervention (1 Day )
    Insulin Lispro Dosing Sequence ABAB   Insulin Lispro Dosing Sequence BABA
STARTED   20   18 
COMPLETED   20   18 
NOT COMPLETED   0   0 

Period 2:   Interval Between Dosing (4-7 Days)
    Insulin Lispro Dosing Sequence ABAB   Insulin Lispro Dosing Sequence BABA
STARTED   20   18 
COMPLETED   20   17 
NOT COMPLETED   0   1 
Withdrawal by Subject                0                1 

Period 3:   Second Intervention (1 Day)
    Insulin Lispro Dosing Sequence ABAB   Insulin Lispro Dosing Sequence BABA
STARTED   20   17 
COMPLETED   20   17 
NOT COMPLETED   0   0 

Period 4:   Interval Between Dosing (4-7 Days)
    Insulin Lispro Dosing Sequence ABAB   Insulin Lispro Dosing Sequence BABA
STARTED   20   17 
COMPLETED   20   17 
NOT COMPLETED   0   0 

Period 5:   Third Intervention (1 Day)
    Insulin Lispro Dosing Sequence ABAB   Insulin Lispro Dosing Sequence BABA
STARTED   20   17 
COMPLETED   20   17 
NOT COMPLETED   0   0 

Period 6:   Interval Between Dosing (4-7 Days)
    Insulin Lispro Dosing Sequence ABAB   Insulin Lispro Dosing Sequence BABA
STARTED   20   17 
COMPLETED   20   16 
NOT COMPLETED   0   1 
Protocol Violation                0                1 

Period 7:   Fourth Intervention (1 Day)
    Insulin Lispro Dosing Sequence ABAB   Insulin Lispro Dosing Sequence BABA
STARTED   20   16 
COMPLETED   20   16 
NOT COMPLETED   0   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Insulin Lispro Dosing Sequence ABAB Each participant was administered insulin lispro A formulation (Treatment A, test – 2 occasions) and insulin lispro B formulation (Treatment B, reference – 2 occasions) in the dosing sequence ABAB.
Insulin Lispro Dosing Sequence BABA Each participant was administered insulin lispro A formulation (Treatment A, test – 2 occasions) and insulin lispro B formulation (Treatment B, reference – 2 occasions) in the dosing sequence BABA.
Total Total of all reporting groups

Baseline Measures
   Insulin Lispro Dosing Sequence ABAB   Insulin Lispro Dosing Sequence BABA   Total 
Overall Participants Analyzed 
[Units: Participants]
 20   18   38 
Age 
[Units: Years]
Mean (Standard Deviation)
 30.4  (7.2)   34.6  (6.4)   32.4  (7.1) 
Gender 
[Units: Participants]
     
Female   0   2   2 
Male   20   16   36 
Race/Ethnicity, Customized 
[Units: Participants]
     
Not Hispanic or Latino   20   18   38 
Hispanic or Latino   0   0   0 
Region of Enrollment 
[Units: Participants]
     
Singapore   20   18   38 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Pharmacokinetic Parameter: Area Under the Serum Insulin Concentration Versus Time Curve From Time Zero to the Last Time Point With a Measurable Concentration [AUC0-tlast]   [ Time Frame: 0 up to 8 hours post dose ]

2.  Secondary:   Pharmacokinetic Parameter: Maximum Serum Insulin Concentration [Cmax]   [ Time Frame: 0 to 8 hours post dose ]

3.  Secondary:   Pharmacodynamic Parameter: Maximum Glucose Infusion Rate (Rmax)   [ Time Frame: 0 to 8 hours post dose ]

4.  Secondary:   Pharmacodynamic Parameter: Time of Maximum Glucose Infusion Rate (tRmax)   [ Time Frame: 0 to 8 hours post dose ]

5.  Secondary:   Pharmacodynamic Parameter: Total Amount of Glucose Infused (Gtot)   [ Time Frame: 0 to 8 hours post dose ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Chief Medical Officer
Organization: Eli Lilly and Company
phone: 800-545-5979



Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01133392     History of Changes
Other Study ID Numbers: 13300
F3Z-EW-IOPY ( Other Identifier: Eli Lilly and Company )
First Submitted: May 27, 2010
First Posted: May 28, 2010
Results First Submitted: October 10, 2014
Results First Posted: December 30, 2014
Last Update Posted: December 30, 2014